Acesion 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  AP30663 / Acesion
    Clinical, Journal:  First Clinical Study with AP30663 - a K 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation. (Pubmed Central) -  Oct 20, 2021   
    In healthy volunteers, no effect of AP30663 was observed on electrocardiographic parameters, other than a concentration-dependent effect on the corrected QT Fridericia's formula interval (+18.8 ± 4.3 ms for the highest dose level compared with time matched placebo). In conclusion, administration of AP30663, a novel K 2 channel inhibitor, was safe and well-tolerated systemically in humans, supporting further development in patients with AF undergoing cardioversion.
  • ||||||||||  AP30663 / Acesion
    Trial completion date, Trial primary completion date:  A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=108, Recruiting, 
    In conclusion, administration of AP30663, a novel K 2 channel inhibitor, was safe and well-tolerated systemically in humans, supporting further development in patients with AF undergoing cardioversion. Trial completion date: Aug 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Dec 2021